The Ministry of Food and Drug Safety announced its plan to pass the revised Pharmaceutical Affairs Act at the National Assembly's plenary session and soft-land the system afterward. The revised Act contains a clause that limits the number of consignees to three for each company that conducts the bioequivalence test for generics and drugs requiring data submission (incrementally modified drugs, iMD).

The Ministry also reaffirmed its position regarding the 1+3 bill for generics and IMDs, on how the bill will partially resolve the rampant drug production issue in Korea, and have a positive influence on preventing recurrence of GMP violations of domestic pharmaceutical manufacturers like Bi